

MEMO FROM THE LABORATORY

DATE: 9/29/2026

Lipoprotein (a) Reference Interval and Result Interpretation

This communication is from:

Shirley Li, M.D., Ph.D.
Director, Clinical Pathology Services
Co-Director, Clinical Chemistry and Toxicology Laboratory

On behalf of:

Heather Stieglitz, Ph.D.
Co-Director, Clinical Chemistry and Toxicology Laboratory

Applicable to: OSUWMC, The James and East Hospitals Medical Staff, and University Reference Laboratory Clients

SUMMARY OF TEST CHANGE

Effective 9/29/26, the Lipoprotein (a) reference interval will be updated to **< 75 nmol/L**. Elevated Lp(a) is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). The 2024 National Lipid Association guidance provides the following interpretive categories:

- < 75 nmol/L: Within the reference range; low Lp(a)-related ASCVD risk
- 75-124 nmol/L: Above the reference range; intermediate Lp(a)-related ASCVD risk
- ≥ 125 nmol/L: Above the reference range; high Lp(a)-related ASCVD risk and considered an ASCVD risk-enhancing factor

The relationship between Lp(a) concentration and ASCVD risk is continuous. Lp(a) results should be interpreted together with the patient's overall cardiovascular risk factors.

1. Koschinsky M, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun;18(3):e308-e319.
2. Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946.

See the online test catalog for more information - [The Ohio State Wexner Medical Center Labs Test Catalog](#)

For questions, please contact: Heather.Stieglitz@osumc.edu

